In AD, preliminary evidence has shown FGF2 improved cognition by modulating ferroptosis and supporting neuronal survival (Li et al., 2025), whereas YAP1 mitigates cognitive deficits and reverses AD pathology via CDK6 signaling (Xu et al., 2021) or artemisinin activation (Zhou et al., 2023). Here, YAP1 is linked to Cognitive impairment.